Nxera Pharma Reaches $10M Milestone in AbbVie Neurological Disease Collaboration

Third milestone payment marks progress in multi-target drug discovery partnership.

Apr. 20, 2026 at 7:03am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a collection of sleek, minimalist glass and metal objects arranged on a clean white background, conceptually representing the collaborative drug discovery process between pharmaceutical companies.Nxera Pharma's productive partnership with AbbVie continues to yield promising advancements in the search for new neurological disease treatments.Cambridge Today

Nxera Pharma, a Japanese biopharmaceutical company, has received a $10 million milestone payment from AbbVie under their multi-target collaboration focused on discovering novel treatments for neurological diseases. This is the third milestone achieved since the partnership began in 2022, reflecting the steady advancement of the pipeline.

Why it matters

The collaboration between Nxera and AbbVie combines Nxera's drug discovery platform with AbbVie's expertise in neurology, aiming to address significant unmet needs in this therapeutic area. Reaching this milestone payment demonstrates the productivity of the partnership and the potential for the pipeline to yield new therapies.

The details

Under the terms of the agreement, Nxera is eligible to receive up to $40 million in near-term research milestones, as well as further potential option, development and commercial milestones totaling up to $1.2 billion, plus tiered royalties on global sales. This current $10 million milestone payment is related to the identification of validated and differentiated 'hit' molecules against a neurology target.

  • The collaboration between Nxera and AbbVie began in 2022.
  • The first milestone was achieved in June 2024.
  • The second milestone was achieved in September 2025.
  • The third milestone, resulting in a $10 million payment to Nxera, was achieved on April 20, 2026.

The players

Nxera Pharma Co., Ltd.

A Japanese biopharmaceutical company focused on developing innovative medicines to address unmet needs, with an agile commercial business in Japan and an extensive pipeline powered by its NxWave drug discovery platform.

AbbVie

A global biopharmaceutical company that collaborates with partners to discover and develop novel treatments, with a focus on neurological diseases.

Christopher Cargill

President and CEO of Nxera Pharma.

Got photos? Submit your photos here. ›

What they’re saying

“This third milestone marks an important step forward in translating our discovery capabilities into a growing pipeline of novel programmes within our collaboration with AbbVie. As this productive partnership continues, we are encouraged by the advancement of multiple targets and the potential to address significant unmet needs in neurological disease.”

— Christopher Cargill, President and CEO of Nxera Pharma

What’s next

Nxera and AbbVie will continue to advance their multi-target collaboration, with Nxera eligible to receive up to $1.2 billion in potential future milestone payments as the pipeline progresses.

The takeaway

The successful collaboration between Nxera and AbbVie demonstrates the potential of Nxera's drug discovery platform to yield promising neurological disease treatments, highlighting the company's capabilities and the value of strategic partnerships in addressing significant unmet medical needs.